Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study

Infections caused by Klebsiella pneumoniae (Kp) carbapenemase (KPC)-producing strains of Kp have become a significant threat in recent years. To assess their outcomes and identify risk factors for 14 day mortality, we conducted a 4 year (2010-13) retrospective cohort study in five large Italian teac...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2015-07, Vol.70 (7), p.2133-2143
Main Authors: Tumbarello, Mario, Trecarichi, Enrico Maria, De Rosa, Francesco Giuseppe, Giannella, Maddalena, Giacobbe, Daniele Roberto, Bassetti, Matteo, Losito, Angela Raffaella, Bartoletti, Michele, Del Bono, Valerio, Corcione, Silvia, Maiuro, Giuseppe, Tedeschi, Sara, Celani, Luigi, Cardellino, Chiara Simona, Spanu, Teresa, Marchese, Anna, Ambretti, Simone, Cauda, Roberto, Viscoli, Claudio, Viale, Pierluigi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacteria
Bacterial infections
Bacterial Proteins - secretion
beta-Lactamases - secretion
Female
Hospitals, Teaching
Humans
Italy - epidemiology
Klebsiella Infections - drug therapy
Klebsiella Infections - epidemiology
Klebsiella Infections - microbiology
Klebsiella Infections - mortality
Klebsiella pneumoniae
Klebsiella pneumoniae - drug effects
Klebsiella pneumoniae - enzymology
Klebsiella pneumoniae - isolation & purification
Male
Medical treatment
Microbial Sensitivity Tests
Middle Aged
Mortality
Regression analysis
Retrospective Studies
Risk Factors
Survival Analysis
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infections caused by Klebsiella pneumoniae (Kp) carbapenemase (KPC)-producing strains of Kp have become a significant threat in recent years. To assess their outcomes and identify risk factors for 14 day mortality, we conducted a 4 year (2010-13) retrospective cohort study in five large Italian teaching hospitals. The cohort included 661 adults with bloodstream infections (BSIs; n = 447) or non-bacteraemic infections (lower respiratory tract, intra-abdominal structure, urinary tract or other sites) caused by a KPC-Kp isolate. All had received ≥48 h of therapy (empirical and/or non-empirical) with at least one drug to which the isolate was susceptible. Most deaths occurred within 2 weeks of infection onset (14 day mortality: 225/661, 34.1%). Logistic regression analysis identified BSI (OR, 2.09; 95% CI, 1.34-3.29), presentation with septic shock (OR, 2.45; 95% CI, 1.47-4.08), inadequate empirical antimicrobial therapy (OR, 1.48; 95% CI, 1.01-2.18), chronic renal failure (OR, 2.27; 95% CI, 1.44-3.58), high APACHE III score (OR, 1.05; 95% CI, 1.04-1.07) and colistin-resistant isolates (OR, 2.18; 95% CI, 1.37-3.46) as independent predictors of 14 day mortality. Combination therapy with at least two drugs displaying in vitro activity against the isolate was associated with lower mortality (OR, 0.52; 95% CI, 0.35-0.77), in particular in patients with BSIs, lung infections or high APACHE III scores and/or septic shock at infection onset. Combinations that included meropenem were associated with significantly higher survival rates when the KPC-Kp isolate had a meropenem MIC of ≤8 mg/L. KPC-Kp infections are associated with high mortality. Treatment with two or more drugs displaying activity against the isolate improves survival, mainly in patients who are critically ill.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkv086